Security
Cogent Biosciences, Inc. Common Stock · COGT
COGTNASDAQCommon stockCurrentCIK 1622229Updated Oct 6, 2026
Name history
Unum Therapeutics Inc. · through Oct 5, 2020Unum Therapeutics, Inc. · through Mar 30, 2018
COGT price & chart
Loading TradingView…
NASDAQ:COGT on TradingView ↗About the company
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
In the news
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) ↗
Recent filings
4 filing
Entry into a Material Definitive Agreement
Items 1.01
4 filing
Other Events
Items 8.01, 9.01
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 425,933,000Source | 384,016,000Source | 834,546,000Source | 274,817,000Source | 429,935,000Source | 903,006,000Source | 283,798,000Source | 476,111,000Source | 937,607,000Source | 327,898,000Source | 313,437,000Source | 300,810,000Source |
| Property, Plant and Equipment, NetUSD | 5,274,000Source | 7,017,000Source | 4,775,000Source | 5,850,000Source | 7,357,000Source | 5,298,000Source | 6,453,000Source | 7,815,000Source | 5,457,000Source | 6,467,000Source | 8,344,000Source | 7,783,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 125,297,000Source | 97,045,000Source | 181,172,000Source | 127,598,000Source | 88,219,000Source | 241,208,000Source | 126,003,000Source | 215,801,000Source | 312,012,000Source | 98,165,000Source | 53,229,000Source | 139,886,000Source |
| Assets, CurrentUSD | 397,244,000Source | 341,528,000Source | 804,820,000Source | 245,008,000Source | 369,971,000Source | 877,803,000Source | 252,884,000Source | 441,903,000Source | 910,355,000Source | 296,472,000Source | 270,771,000Source | 264,966,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,354,000Source | 6,009,000Source | 12,520,000Source | 7,160,000Source | 6,755,000Source | 11,425,000Source | 7,223,000Source | 6,163,000Source | 9,590,000Source | 9,395,000Source | 5,061,000Source | 4,435,000Source |
| Operating Lease, Right-of-Use AssetUSD | 18,591,000Source | 20,580,000Source | 22,596,000Source | 19,097,000Source | 21,057,000Source | 17,549,000Source | 19,599,000Source | 21,531,000Source | 18,078,000Source | 20,097,000Source | 21,998,000Source | 23,316,000Source |
| Other Assets, NoncurrentUSD | 4,488,000Source | 4,862,000Source | 1,939,000Source | 4,862,000Source | 4,862,000Source | 1,940,000Source | 4,862,000Source | 4,862,000Source | 3,301,000Source | 4,862,000Source | 4,864,000Source | 4,745,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 123,469,000Source | 69,357,000Source | 302,158,000Source | 119,781,000Source | 56,712,000Source | 295,313,000Source | 64,803,000Source | 53,777,000Source | 301,236,000Source | 71,612,000Source | 55,635,000Source | 45,075,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 141,000Source | 110,000Source | 171,000Source | 114,000Source | 109,000Source | 171,000Source | 114,000Source | 96,000Source | 161,000Source | 110,000Source | 86,000Source | 70,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,085,928,000Source | -791,556,000Source | -1,382,177,000Source | -1,004,998,000Source | -720,922,000Source | -1,285,772,000Source | -931,469,000Source | -661,972,000Source | -1,188,420,000Source | -859,483,000Source | -603,624,000Source | -411,214,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 208,000Source | 896,000Source | -770,000Source | 13,000Source | -192,000Source | -415,000Source | 164,000Source | -39,000Source | 355,000Source | 447,000Source | 246,000Source | -104,000Source |
| Stockholders' Equity Attributable to ParentUSD | 302,464,000Source | 314,659,000Source | 532,388,000Source | 155,036,000Source | 373,223,000Source | 607,693,000Source | 218,995,000Source | 422,334,000Source | 636,371,000Source | 256,286,000Source | 257,802,000Source | 255,735,000Source |
| Additional Paid in Capital, Common StockUSD | 1,280,128,000Source | 994,609,000Source | 1,850,411,000Source | 1,051,992,000Source | 980,108,000Source | 1,828,956,000Source | 1,042,021,000Source | 862,096,000Source | 1,734,882,000Source | 1,004,612,000Source | 801,059,000Source | 601,153,000Source |
| Liabilities and EquityUSD | 425,933,000Source | 384,016,000Source | 834,546,000Source | 274,817,000Source | 429,935,000Source | 903,006,000Source | 283,798,000Source | 476,111,000Source | 937,607,000Source | 327,898,000Source | 313,437,000Source | 300,810,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 62,246,000Source | 53,048,000Source | 59,296,000Source | 58,422,000Source | 40,003,000Source | 57,981,000Source | 49,318,000Source | 36,686,000Source | 63,953,000Source | 55,710,000Source | 38,168,000Source | 26,849,000Source |
| Operating Lease, Liability, CurrentUSD | 1,706,000Source | 1,520,000Source | 1,489,000Source | 1,658,000Source | 1,475,000Source | 1,383,000Source | 1,611,000Source | 1,432,000Source | 1,547,000Source | 1,565,000Source | 1,386,000Source | 1,423,000Source |
| Accounts Payable, CurrentUSD | 16,029,000Source | 15,061,000Source | 7,488,000Source | 16,625,000Source | 8,975,000Source | 13,744,000Source | 14,154,000Source | 15,565,000Source | 9,504,000Source | 12,013,000Source | 10,655,000Source | 5,842,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,603,000Source | 16,309,000Source | 19,315,000Source | 15,051,000Source | 16,709,000Source | 14,097,000Source | 15,480,000Source | 17,091,000Source | 14,355,000Source | 15,902,000Source | 17,467,000Source | 18,226,000Source |
| Other Liabilities, NoncurrentUSD | 2,370,000Source | — | 90,000Source | 2,359,000Source | — | 62,000Source | 5,000Source | — | 33,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Long-term DebtUSD | 44,250,000Source | — | 223,457,000Source | 43,949,000Source | — | 223,173,000Source | — | — | 222,895,000Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | —Source | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -97,352,000Source | -71,986,000Source | -328,937,000Source | -255,859,000Source | -192,410,000Source | -140,241,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 16,908,000Source | 10,008,000Source | 46,079,000Source | 39,740,000Source | 30,621,000Source | 18,368,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 4,240,000Source | 2,141,000Source | -2,509,000Source | 1,358,000Source | 4,813,000Source | 2,359,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -86,883,000Source | -66,511,000Source | -264,444,000Source | -207,791,000Source | -153,624,000Source | -118,638,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -36,457,000Source | 69,379,000Source | -399,526,000Source | 38,276,000Source | -97,824,000Source | -124,718,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 449,000Source | 547,000Source | 1,554,000Source | 573,000Source | 2,796,000Source | 6,863,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 48,896,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 52,536,000Source | 24,970,000Source | 878,233,000Source | 214,451,000Source | 163,536,000Source | 163,558,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -70,804,000Source | 27,838,000Source | 214,263,000Source | 44,936,000Source | -87,912,000Source | -79,798,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 125,633,000Source | 97,045,000Source | 181,588,000Source | 127,598,000Source | 241,624,000Source | 126,003,000Source | 312,428,000Source | 98,165,000Source | 53,229,000Source | 141,141,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 2,015,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 10,604,000Source | 10,358,000Source | 17,107,000Source | 9,716,000Source | 16,908,000Source | 10,008,000Source | 46,079,000Source | 39,740,000Source | 30,621,000Source | 18,368,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 278,000Source | 0Source | 601,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 2,564,000Source | 2,450,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -135,000Source | 0Source | 0Source | 0Source | -8,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -7,181,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 14,366,000Source | 11,800,000Source | 31,827,000Source | 13,379,000Source | 28,242,000Source | 11,904,000Source | 63,583,000Source | 43,281,000Source | 34,375,000Source | 26,212,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 1,459,000Source | — | 1,217,000Source | 314,000Source | 1,213,000Source | — | 3,062,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 3,887,000Source | 4,779,000Source | 7,461,000Source | 2,373,000Source | 7,608,000Source | 2,952,000Source | 14,689,000Source | 18,088,000Source | 13,077,000Source | 3,989,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -80,930,000Source | -70,634,000Source | -96,405,000Source | -73,529,000Source | -97,352,000Source | -71,986,000Source | -328,937,000Source | -255,859,000Source | -192,410,000Source | -140,241,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -70,634,000Source | — | — | — | — | — | — | -192,410,000Source | -140,241,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,425,000Source | 4,780,000Source | 6,233,000Source | 2,053,000Source | 6,255,000Source | 2,947,000Source | 4,426,000Source | 20,080,000Source | 15,720,000Source | 7,598,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | -396,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -3,000Source | 1,000Source | -11,000Source | -6,000Source | -140,000Source | -5,000Source | -20,000Source | 1,992,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | 161,819,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 49,291,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 5,756,000Source | 136,000Source | 11,546,000Source | 199,000Source | 965,000Source | 1,238,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -83,355,000Source | -75,414,000Source | -102,638,000Source | -75,582,000Source | -103,607,000Source | -74,933,000Source | -333,363,000Source | -275,939,000Source | -208,130,000Source | -147,839,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -3,000Source | 1,000Source | -11,000Source | -6,000Source | -140,000Source | -5,000Source | -20,000Source | 1,992,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -80,930,000Source | -70,634,000Source | -96,405,000Source | -73,529,000Source | -97,352,000Source | -71,986,000Source | -328,937,000Source | -255,859,000Source | -192,410,000Source | -140,241,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.5Source | -0.52Source | -0.52Source | -0.53Source | -0.53Source | -0.52Source | -2.16Source | -1.94Source | -2.42Source | -2.39Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.5Source | -0.52Source | -0.52Source | -0.53Source | -0.53Source | -0.52Source | -2.16Source | -1.94Source | -2.42Source | -2.39Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 137,550,159Source | 110,165,580Source | 171,005,468Source | 114,466,080Source | 162,194,778Source | 113,307,940Source | 128,899,408Source | 103,856,611Source | 79,657,942Source | 58,739,713Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 137,550,159Source | 110,165,580Source | 171,005,468Source | 114,466,080Source | 162,194,778Source | 113,307,940Source | 128,899,408Source | 103,856,611Source | 79,657,942Source | 58,739,713Source |
| Interest Expense (non-operating)USD | — | — | 1,459,000Source | — | 1,217,000Source | 314,000Source | 1,213,000Source | — | 3,062,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 83,355,000Source | 75,414,000Source | 102,638,000Source | 75,582,000Source | 103,607,000Source | 74,933,000Source | 333,363,000Source | 275,939,000Source | 208,130,000Source | 147,839,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 626,000Source | 640,000Source | 2,600,000Source | 2,500,000Source | 2,270,000Source | 842,000Source |
| General and Administrative ExpenseUSD | — | — | 14,366,000Source | 11,800,000Source | 31,827,000Source | 13,379,000Source | 28,242,000Source | 11,904,000Source | 63,583,000Source | 43,281,000Source | 34,375,000Source | 26,212,000Source |
| Investment Income, InterestUSD | — | — | 3,887,000Source | 4,779,000Source | 7,461,000Source | 2,373,000Source | 7,608,000Source | 2,952,000Source | 14,689,000Source | 18,088,000Source | 13,077,000Source | 3,989,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -70,634,000Source | — | — | — | — | — | — | -192,410,000Source | -140,241,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,425,000Source | 4,780,000Source | 6,233,000Source | 2,053,000Source | 6,255,000Source | 2,947,000Source | 4,426,000Source | 20,080,000Source | 15,720,000Source | 7,598,000Source |
| Research and Development ExpenseUSD | — | — | 68,989,000Source | 63,614,000Source | 70,811,000Source | 62,203,000Source | 75,365,000Source | 63,029,000Source | 269,780,000Source | 232,658,000Source | 173,755,000Source | 121,627,000Source |
Filing attachments
cogt-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 cogt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 Completed onboarding of expert cross-functional Cogent customer-facing team, including all field-based commercial and medical team members …
Read attachment ↗cogt-ex4_1.htm · 10-Q · 2026-05-05
Exhibit 4.1 SECOND SUPPLEMENTAL INDENTURE This SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of April 27, 2026, is between COGENT BIOSCIENCES, INC. (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as trustee (the “Trustee”). WHEREAS, the Company and the Trustee are party to a Base Indenture dated as of November 18, 2025 (the “Base Indenture”) and a First Supplemental Indenture dated as of November 18, 2025 (the “First Supplemental Indenture” and, …
Read attachment ↗cogt-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 cogt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO annual meeting - Ended 1Q 2026 with $866.4 million in cash, sufficient to fund operations into 2028 WALTHAM, Mass. and BOULDER…
Read attachment ↗cogt-ex4_1.htm · 10-K · 2026-02-17
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED DESCRIPTION OF CAPITAL STOCK General The following is a summary of the material terms of our capital stock, as well as other material terms of certain provisions of the Delaware General Corporation Law, our fourth restated certificate of incorporation (as amended from time to time, our “certificate of incorporation”), and our second amended and restated…
Read attachment ↗cogt-ex99_1.htm · 8-K · 2026-02-17
Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results • SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 • PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026 • Six abstracts …
Read attachment ↗